Low Adderall sales hit Shire
pharmafile | February 22, 2010 | News story | Sales and Marketing | 2009 financials, Adderall, Shire
Shire has posted negative growth due to generic competition for its flagship ADHD drug Adderall XR.
Product sales were down 2% to $2.7 billion as Adderall sales dropped 43% to $627 million following the launch of generic versions by Teva in April and Impax in October 2009.
Excluding sales of Adderall XR, Shire’s core product sales were up 28% to $2.1 billion on a constant exchange rate basis.
Chief executive Angus Russell said: “Our growth prospects remain excellent and our core product portfolio currently has robust exclusivity protection. We have launched Intuniv successfully in the US; we plan to launch velaglucerase alfa (VPRIV) imminently, and there is also an opportunity for Replagal to enter the US market.
“Vyvanse, our leading ADHD treatment with a current monthly US ADHD market share of 13.6%, continues to grow and build strong brand recognition in the US and has recently been launched in Canada. Adderall XR continues to generate value from both product sales and a considerable royalty stream.
“We have also demonstrated a pro-active approach to cost management in 2009 as promised, and have the opportunity to leverage our existing infrastructure to deliver expanding margins in the future.”
Shire has a number of potential product launches in 2010, pending regulatory review.
These include: Vpriv, indicated for the treatment of Gaucher’s disease; Replagal, for the treatment of Fabry disease; Equasym, for the treatment of ADHD in selected EU countries and Vyvanse, indicated for the treatment of ADHD in Canada.
Despite a full year loss, Russell said he remains confident that Shire will meet its target of mid-teen revenue growth on average between 2009 and 2015 on the strength of its pipeline.
Related Content
Takeda plans to vacate all 1,000 staff from US HQ by the year’s end
Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, …
Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion
Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss …
Top Ten most popular articles on Pharmafile.com this week!
With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger …
